REVIEW PAPER
Harnessing nature – plant compunds as potential breakthrough therapeutics for Parkinon’s Disease
1
Medical Department, Jagiellonian University Collegium Medicum, Kraków, Poland
Corresponding author
J Pre Clin Clin Res. 2024;18(3):293-298
KEYWORDS
TOPICS
ABSTRACT
Introduction and objective:
Parkinson disease (PD) is the second most common progressive neurodegenerative disorder. Aetiology evolves around atrophy of dopaminergic neurons located in the substantia nigra. The main ailments that impair motricity include generalized bradykinesia and at least one other symptom of resting tremor or rigidity. In addition to cardinal PD symptoms, the disease can also cause a range of non-motor disabilities. The aim of the review is to describe natural plantorigin substances currently being tested in specific PD models that could become detrimental to PD management in the future.
Review methods:
A search of PubMed was conducted for original articles examining the use of natural plant-derived products in animal or cell models of PD. Two search formulations were used to broaden the scope of the results: ‘natural product’ and ‘plant’, and ‘Parkinson’s disease’ and ‘natural product, and ‘herb’ and ‘Parkinson’s disease’.
Brief description of the state of knowledge:
Currently, it is thought that at the molecular level, substantia nigra atrophy may be related to the accumulation of abnormal proteins in the form of Levy bodies (LBs), mitochondrial disorders, neuroinflammation, and disruption of the blood–brain barrier (BBB) function. In recent years, many etiologies of PD have been indicated. Current state-of-the-art treatments for PD are only symptomatic, and causative medication is unavailable
Summary:
The use of natural components is very promising in the current search for effective PD treatments. Their mechanism of action is based on complex molecular mechanisms, the disorders of which are the basis for the occurrence of PD in humans. Harnessing the therapeutic potential of these natural compounds may be crucial for the future treatment of PD patients. However, rigorous evaluation of pharmacokinetics, bioavailability, among others, need to be established.
Parkinson disease (PD) is the second most common progressive neurodegenerative disorder. Aetiology evolves around atrophy of dopaminergic neurons located in the substantia nigra. The main ailments that impair motricity include generalized bradykinesia and at least one other symptom of resting tremor or rigidity. In addition to cardinal PD symptoms, the disease can also cause a range of non-motor disabilities. The aim of the review is to describe natural plantorigin substances currently being tested in specific PD models that could become detrimental to PD management in the future.
Review methods:
A search of PubMed was conducted for original articles examining the use of natural plant-derived products in animal or cell models of PD. Two search formulations were used to broaden the scope of the results: ‘natural product’ and ‘plant’, and ‘Parkinson’s disease’ and ‘natural product, and ‘herb’ and ‘Parkinson’s disease’.
Brief description of the state of knowledge:
Currently, it is thought that at the molecular level, substantia nigra atrophy may be related to the accumulation of abnormal proteins in the form of Levy bodies (LBs), mitochondrial disorders, neuroinflammation, and disruption of the blood–brain barrier (BBB) function. In recent years, many etiologies of PD have been indicated. Current state-of-the-art treatments for PD are only symptomatic, and causative medication is unavailable
Summary:
The use of natural components is very promising in the current search for effective PD treatments. Their mechanism of action is based on complex molecular mechanisms, the disorders of which are the basis for the occurrence of PD in humans. Harnessing the therapeutic potential of these natural compounds may be crucial for the future treatment of PD patients. However, rigorous evaluation of pharmacokinetics, bioavailability, among others, need to be established.
Łach A, Cytlau B, Skorupa M, Marczyk Ł. Harnessing nature – plant compunds as potential breakthrough therapeutics for Parkinon’s Disease.
J Pre-Clin Clin Res. 2024; 18(3): 293–298. doi: 10.26444/jpccr/192629
REFERENCES (42)
1.
Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol. 2016;15(12):1257–1272. https://doi.org/10.1016/S1474-....
2.
Hu S, Tan J, Qin L, et al. Molecular chaperones and Parkinson’s disease. Neurobiol Dis. 2021;160:105527. https://doi.org/10.1016/j.nbd.....
3.
Hang L, Thundyil J, Lim KL. Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection. Ann N Y Acad Sci. 2015;1350:37–47. https://doi.org/10.1111/nyas.1....
4.
Tansey MG, Wallings RL, Houser MC, et al. Inflammation and immune dysfunction in Parkinson disease. Nat Rev Immunol. 2022;22(11):657–673. https://doi.org/10.1038/s41577....
5.
Pediaditakis I, Kodella KR, Manatakis DV, et al. Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption. Nat Commun. 2021;12(1):5907. https://doi.org/10.1038/s41467....
6.
Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson’s disease. Lancet Neurol. 2020;19(2):170–178. https://doi.org/10.1016/S1474-....
7.
Park SJ, Jin U, Park SM. Interaction between coxsackievirus B3 infection and α-synuclein in models of Parkinson’s disease. PLoS Pathog. 2021;17(10):e1010018. https://doi.org/10.1371/journa....
8.
Onisiforou A, Spyrou GM. Identification of viral-mediated pathogenic mechanisms in neurodegenerative diseases using network-based approaches. Brief Bioinform. 2021;22(6):bbab141. https://doi.org/10.1093/bib/bb....
9.
Ward RJ, Zucca FA, Duyn JH, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13(10):1045–1060. https://doi.org/10.1016/S1474-....
10.
Salim S, Ahmad F, Banu A, et al. Gut microbiome and Parkinson’s disease: Perspective on pathogenesis and treatment. J Adv Res. 2023;50:83–105. https://doi.org/10.1016/j.jare....
11.
Parkinson’s Disease Risk Factors and Causes. https://www. hopkinsmedicine.org/health/conditions-and-diseases parkinsonsdisease/parkinsons-disease-risk-factors-and-causes (access 2024.07.04).
12.
Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016;34(4):955–965. https://doi.org/10.1016/j.ncl.....
13.
Parkinson’s disease in adults NICE guideline [NG71]. https://www.nice. org.uk/guidance/ng71/chapter/Recommendations#pharmacologicalmanagement-of-motor-symptoms (access 2024.07.04).
14.
Xu X, Han C, Wang P, et al. Natural products targeting cellular processes common in Parkinson’s disease and multiple sclerosis [published correction appears in Front Neurol. 2023 Dec 22;14:1350223. https:// doi.org/10.3389/fneur.2023.1350223]. Front Neurol. 2023;14:1149963. https://doi.org/10.3389/fneur.....
15.
Kim SW, Lee JH, Kim B, et al. Natural Products as the Potential to Improve Alzheimer’s and Parkinson’s Disease. Int J Mol Sci. 2023;24(10):8827. https://doi.org/10.3390/ijms24....
16.
Bae HK, Chung SK. Antioxidant and antimicrobial activity of solvent fractions from black bamboo leaves. Korean Journal of Food Preservation, 2014;21(4):560–564. https://doi.org/10.11002/kjfp.....
17.
Lee HJ, Dhodary B, Lee JY, et al. Dereplication of Components Coupled with HPLC-qTOF-MS in the Active Fraction of Humulus japonicus and It’s Protective Effects against Parkinson’s Disease Mouse Model. Molecules. 2019;24(7):1435. https:/ doi.org/10.3390/molecules24071435.
18.
Sharma N, Radha, Kumar M, et al. Aegle marmelos (L.) Correa: An Underutilized Fruit with High Nutraceutical Values: A Review. Int J Mol Sci. 2022;23(18):10889. https://doi.org/10.3390/ijms23....
19.
Derf A, Sharma A, Bharate SB, et al. Aegeline, a natural product from the plant Aegle marmelos, mimics the yeast SNARE protein Sec22p in suppressing?-synuclein and Bax toxicity in yeast [published correction appears in Bioorg Med Chem Lett. 2019 Aug 15;29(16):2437–2438. doi: 10.1016/j.bmcl.2019.06.053]. Bioorg Med Chem Lett. 2019;29(3):454– 460. https://doi.org/10.1016/j.bmcl....
20.
Lopresti AL, Smith SJ, Drummond PD. Herbal treatments for migraine: A systematic review of randomised-controlled studies. Phytother Res. 2020;34(10):2493–2517. https://doi.org/10.1002/ptr.67....
21.
Liu Q, Zhang S, Zhu D, et al. The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson’s disease in mice. Behav Brain Res. 2020;379:112337. https:// doi.org/10.1016/j.bbr.2019.112337.
22.
Leung AY, Foster S. Encyclopedia of Common Natural Ingredients Used in Food, Drugs and Cosmetics. 2nd ed. New York: John Wiley and Sons, Inc.; 1996. p. 332–334.
23.
Anthoni C, Laukoetter MG, Rijcken E, et al. Mechanisms underlying the anti-inflammatory actions of boswellic acid derivatives in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2006;290(6):G1131-G1137. https://doi.org/10.1152/ajpgi.....
24.
Shadfar S, Khanal S, Bohara G, et al. Methanolic Extract of Boswellia serrata Gum Protects the Nigral Dopaminergic Neurons from Rotenone-Induced Neurotoxicity. Mol Neurobiol. 2022;59(9):5874–5890. https:// doi.org/10.1007/s12035-022-02943-y.
25.
Silva-Martins S, Beserra-Filho JIA, Maria-Macêdo A, et al. Myrtenol complexed with β-cyclodextrin ameliorates behavioural deficits and reduces oxidative stress in the reserpine-induced animal model of Parkinsonism. Clin Exp Pharmacol Physiol. 2021;48(11):1488–1499. https://doi.org/10.1111/1440-1....
26.
Chen Y, Li G, Law HCH, et al. Determination of Oxyphylla A Enantiomers in the Fruits of Alpinia oxyphylla by a Chiral High- Performance Liquid Chromatography-Multiple Reaction Monitoring- Mass Spectrometry Method and Comparison of Their In Vivo Biological Activities [published correction appears in J Agric Food Chem. 2021 Jan 20;69(2):860. https://doi.org/10.1021/acs.ja...]. J Agric Food Chem. 2020;68(40):11170–11181. https://doi.org/10.1021/acs. jafc.0c04031.
27.
Li G, Zhang Z, Quan Q, et al. Discovery, Synthesis, and Functional Characterization of a Novel Neuroprotective Natural Product from the Fruit of Alpinia oxyphylla for use in Parkinson’s Disease Through LC/MS-Based Multivariate Data Analysis-Guided Fractionation. J Proteome Res. 2016;15(8):2595–2606. https://doi.org/10.1021/acs. jproteome.6b00152.
28.
Lee J, Lee YM, Lee BW, et al. Chemical constituents from the aerial parts of Aster koraiensis with protein glycation and aldose reductase inhibitory activities. J Nat Prod. 2012;75(2):267–270. https://doi. org/10.1021/np200646e.
29.
Kwon J, Ko K, Zhang L, et al. An Autophagy Inducing Triterpene Saponin Derived from Aster koraiensis. Molecules. 2019;24(24):4489. https://doi.org/10.3390/molecu....
30.
Fraige K, Dametto AC, Zeraik ML, et al. Dereplication by HPLCDAD- ESI-MS/MS and Screening for Biological Activities of Byrsonima Species (Malpighiaceae). Phytochem Anal. 2018;29(2):196–204. https:// doi.org/10.1002/pca.2734.
31.
de Assis ALC, de Araújo Rodrigues P, de Morais SM, et al. Byrsonima sericea Ethanol Extract Protected PC12 Cells from the Oxidative Stress and Apoptosis Induced by 6-Hydroxydopamine. Neurochem Res. 2024;49(1):234–244. https://doi.org/10.1007/s11064....
32.
Leonoudakis D, Rane A, Angeli S, et al. Anti-Inflammatory and Neuroprotective Role of Natural Product Securinine in Activated Glial Cells: Implications for Parkinson’s Disease. Mediators Inflamm. 2017;2017:8302636. https://doi.org/10.1155/2017/8....
33.
Li H, Kim J, Tran HNK, et al. Extract of Polygala tenuifolia, Angelica tenuissima, and Dimocarpus longan Reduces Behavioral Defect and Enhances Autophagy in Experimental Models of Parkinson’s Disease. Neuromolecular Med. 2021;23(3):428–443. https://doi.org/10.1007/ s12017-020-08643-x.
34.
Li YY, Lin YK, Liu XH, et al. Leonurine: From Gynecologic Medicine to Pleiotropic Agent. Chin J Integr Med. 2020;26(2):152–160. https://doi.org/10.1007/s11655....
35.
Lin XM, Pan MH, Sun J, et al. Membrane phospholipid peroxidation promotes loss of dopaminergic neurons in psychological stress-induced Parkinson’s disease susceptibility. Aging Cell. 2023;22(10):e13970. https://doi.org/10.1111/acel.1....
36.
Pang M, Peng R, Wang Y, et al. Molecular understanding of the translational models and the therapeutic potential natural products of Parkinson’s disease. Biomed Pharmacother. 2022;155:113718. https:// doi.org/10.1016/j.biopha.2022.113718.
37.
Lee JH, Kim HJ, Kim JU, et al. A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer’s and Parkinson’s Disease. Int J Mol Sci. 2021;22(3):1324. https://doi.org/10.3390/ijms22....
38.
Mohammed S, Russo I, Ramazzina I. Uncovering the Role of Natural and Synthetic Small Molecules in Counteracting the Burden of α-Synuclein Aggregates and Related Toxicity in Different Models of Parkinson’s Disease. Int J Mol Sci. 2023;24(17):13370. https://doi.org/10.3390/ ijms241713370.
39.
Bhusal CK, Uti DE, Mukherjee D, et al. Unveiling Nature’s potential: Promising natural compounds in Parkinson’s disease management. Parkinsonism Relat Disord. 2023;115:105799. https://doi.org/10.1016/j. parkreldis.2023.105799.
40.
Mohammadipour A. A focus on natural products for preventing and cure of mitochondrial dysfunction in Parkinson’s disease. Metab Brain Dis. 2022;37(4):889–900. https://doi.org/10.1007/s11011....
41.
Solayman M, Islam MA, Alam F, et al. Natural Products Combating Neurodegeneration: Parkinson’s Disease. Curr Drug Metab. 2017;18(1):50–61. https://doi.org/10.2174/138920....
42.
Singh A, Tripathi P, Yadawa AK, et al. Promising Polyphenols in Parkinson’s Disease Therapeutics. Neurochem Res. 2020;45(8):1731– 1745. https://doi.org/10.1007/s11064....
Share
RELATED ARTICLE
| eISSN: | 1898-7516 |
| ISSN: | 1898-2395 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
